Page 82 - 86_04

CM. Transmission of hepatitis C by intrahepatic inoculation with trans-
cribed RNA. Science 1997; 277(5325):570–4.
27. Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single
full-length cDNA clone of hepatitis C virus are infectious when directly
transfected into the liver of a chimpanzee. Proc Natl Acad Sci 1997;
94(16):8738–43.
28. Sakai A, Claire MS, Faulk K, Govindarajan S, Emerson SU, Purcell RH,
et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and
contains functionally important genotype-specific sequences. Proc Natl
Acad Sci 2003; 100(20):11646–51.
29. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for sub-
genomic and genomic hepatitis C virus RNA replication. J Virol 2002;
76(24):13001–14.
30. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager
R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell
line. Science 1999; 285(5424):110–3.
31. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA re-
plication in cell culture. Science 2000; 290(5498):1972–4.
32. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M,
et al. Efficient replication of the genotype 2a hepatitis C virus subgeno-
mic replicon. YGAST 2003; 125(6):1808–17.
33. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Stein-
mann E, et al. Construction and characterization of infectious intrage-
notypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad
Sci 2006; 103(19):7408–13.
34. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al.
Production of infectious hepatitis C virus in tissue culture from a cloned
viral genome. Nat Med 2005; 11(7):791–6.
35. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC,
et al. Complete replication of hepatitis C virus in cell culture. Science
2005; 309(5734):623–6.
36. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ,
McKeating JA, et al. Cell culture-grown hepatitis C virus is infectious in
vivo and can be recultured in vitro. Proc Natl Acad Sci 2006;
103(10):3805–9.
37. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al.
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci 2005;
102(26):9294–9.
38. Steinmann E, Pietschmann T. Cell Culture Systems for Hepatitis C Virus.
In: Bartenschlager R, editor. Hepatitis C Virus: From Molecular Virology
to Antiviral Therapy. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013.
pp. 17–48. (Current Topics in Microbiology and Immunology; vol. 369).
39. Kim NG, Kullar R, Khalil H, Saab S. Meeting the WHO hepatitis C virus
elimination goal: Review of treatment in paediatrics. J Viral Hepat. 2020;
27(8):762–9.
Scientific session held on november 26, 2020 to commemorate
298 the nobel awards in physiology or medicine and in chemistry 2020
Juan Ramón Lacadena, Pablo Gastaminza, Lluis Montoliu
An. Real Acad. Farm. Vol. 86. Nº4 (2020) · pp. 287- 310
ANALES
RANF
www.analesranf.com
40. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Cha-
racterization of the hepatitis C virus-encoded serine proteinase: deter-
mination of proteinase-dependent polyprotein cleavage sites. J Virol
1993; 67(5):2832–43.
41. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, et al.
Crystal structure of the hepatitis C virus NS3 protease domain complexed
with a synthetic NS4A cofactor peptide. Cell 1996; 87(2):343–55.
42. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC.
Crystal structure of the RNA-dependent RNA polymerase from hepatitis
C virus reveals a fully encircled active site. Nat Struct Biol 1999;
6(10):937–43.
43. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, et al.
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C
virus. Proc Natl Acad Sci 1999;96(23):13034–9.
44. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P,
et al. An NS3 protease inhibitor with antiviral effects in humans infected
with hepatitis C virus. Nature 2003; 426(6963):186–9.
45. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat
Rev Micro 2007; 5(6):453–63.
46. Bartenschlager R. Hepatitis C virus replicons: potential role for drug
development. Nat Rev Drug Discov 2002; 1(11):911–6.
47. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et
al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a
potent clinical effect. Nature 2010; 465(7294):96–100.
48. Sofia MJ. Beyond sofosbuvir: what opportunity exists for a better nu-
cleoside/nucleotide to treat hepatitis C? Antiviral Res. 2014; 107:119–
24.
49. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up
prevention and treatment towards the elimination of hepatitis C: a global
mathematical model. Lancet 2019; 393(10178):1319–29.